New asthma drug QL2302 goes Head-to-Head with tezspire in major trial
NCT ID NCT07302516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug called QL2302 works as well as the approved drug Tezspire for people with severe asthma that is not controlled by current treatments. About 636 adults aged 18-80 will receive injections every 4 weeks for 48 weeks, then be monitored for another 12 weeks. The main goal is to see if QL2302 can reduce asthma attacks as effectively as Tezspire.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?